ClearBridge Investments released its second-quarter 2025 investor letter, noting growth stocks leading the market rebound from tariff uncertainty. The Russell 3000 Growth Index rose 17.6%, outperforming the Value Index by over 1,300 basis points. The Strategy underperformed its benchmark in Q2, check its top five holdings for 2025 picks.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was highlighted in ClearBridge All Cap Growth Strategy’s Q2 2025 investor letter. With a one-month return of 6.42% and a 52-week gain of 69.98%, ALNY closed on August 29, 2025, at $446.51 per share, boasting a market cap of $58.528 billion.

ClearBridge All Cap Growth Strategy added Alnylam Pharmaceuticals, Inc. (ALNY) to its portfolio, praising the biotech company’s RNA interference technology and therapeutic potential. The company’s core Amvuttra franchise for liver conditions and diverse drug pipeline show promise for future growth and innovation.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was not among the 30 most popular stocks held by hedge funds in Q2 2025. While acknowledging ALNY’s investment potential, some believe other AI stocks offer greater upside with less risk. For a report on an undervalued AI stock poised for growth, check out the free report on the best short-term AI stock.

Read more at Yahoo Finance: Should You Add Alnylam Pharmaceuticals (ALNY) to Your Portfolio?